Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763383 | 1.00 | HPGD (0.42) | HPGDCYP4F2CYP4A11CNR2CNR1 | |
| SCHEMBL2763382 | 1.00 | HPGD (0.42) | HPGDCYP4F2CYP4A11CNR2CNR1 | |
| SCHEMBL2763604 | 0.89 | MAP4K4 (0.41) | HPGDCNR2ATMKCNK3ALDH1A1 | |
| SCHEMBL14945497 | 0.89 | ATM (0.40) | HPGDCNR2ATMKCNK3ALDH1A1 | |
| SCHEMBL2763606 | 0.89 | MAP4K4 (0.41) | HPGDCNR2ATMKCNK3ALDH1A1 | |
| SCHEMBL2623659 | 0.89 | MAP4K4 (0.41) | HPGDCNR2ATMKCNK3ALDH1A1 | |
| SCHEMBL2764387 | 0.87 | CNR2 (0.43) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL2764390 | 0.87 | CNR2 (0.43) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL17049671 | 0.87 | CNR2 (0.43) | CNR2KCNK3ALDH1A1THRBBLM | |
| SCHEMBL2632355 | 0.87 | CNR2 (0.43) | CNR2KCNK3ALDH1A1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9024067-B2 | Process for preparing carboxylic acid amides useful in the treatment of muscular disorders | CANBEX THERAPEUTICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024067-B2 | Process for preparing carboxylic acid amides useful in the treatment of muscular disorders | CANBEX THERAPEUTICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130123356-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2013-05-16 | — | — | US | disclosed |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010116116-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2010-10-14 | — | — | WO | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| EP-1745011-B1 | MODULATORS OF CANNABINOID RECEPTORS | UCL BUSINESS PLC (GB) | 2009-09-30 | — | — | EP | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114062-A1 | Modulator | CHRNA3, CHRM3, NR3C2 | HPGD 2698/4885CYP4F2 380/4885CYP4A11 279/4885 |
| US-20160107984-A1 | MODULATOR | CHRNA3, CHRNB3, CHRM3 | HPGD 1896/4885CYP4F2 525/4885CYP4A11 435/4885 |
| US-20130123356-A1 | MODULATOR | MRGPRX2, NR3C2, MC2R | HPGD 750/4885CYP4F2 213/4885CYP4A11 22/4885 |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | CPT1B, MUSK, C1R | HPGD 2246/4885CYP4F2 523/4885CYP4A11 566/4885 |
| US-20100144876-A1 | MODULATOR | CHRNA3, CHRM3, NR3C2 | HPGD 2698/4885CYP4F2 380/4885CYP4A11 279/4885 |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | HPGD 2385/4885CYP4F2 765/4885CYP4A11 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.